🇺🇸 FDA
Company

BioXcel

BioXcel Therapeutics

BTAI pharma USA

Quick answer

BioXcel is a pharma company (BTAI) headquartered in NEW HAVEN, CT, USA with 17 tracked pipeline programs.

Pipeline (17)

project

BXCL501

Agitation

Phase 3 · small_molecule · completed

4 trials project

BXCL501

Agitation,Psychomotor

Phase 3 · small_molecule · completed

1 trials project

Sublingual film containing Dexmedetomidine (BXCL501)

Agitation Associated With Bipolar Disorder

Phase 3 · small_molecule · completed

1 trials project

Sublingual film containing dexmedetomidine (BXCL501)

Agitation

Phase 3 · small_molecule · completed

1 trials project

BXCL501 Sublingual Film

Bipolar I Disorder

Phase 2 · small_molecule · completed

1 trials project

BXCL701

Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 · small_molecule · active

1 trials project

BXCL701 plus Pembrolizumab

Prostate Cancer

Phase 2 · small_molecule · completed

1 trials project

Dexmedetomidine

Opioid Withdrawal

Phase 2 · small_molecule · completed

1 trials project

Dexmedetomidine sublingual film

Delirium

Phase 2 · small_molecule · terminated

1 trials project

Sublingual film containing Dexmedetomidine

Agitation,Psychomotor

Phase 2 · small_molecule · completed

1 trials project

BXCL501 80 Micrograms

Schizophrenia

Phase 1 · small_molecule · active

1 trials project

Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg

Alcohol Use Disorder (AUD)

Phase 1 · small_molecule · active

1 trials project

Placebo

Alcohol Use Disorder (AUD)

Phase 1 · small_molecule · completed

1 trials project

Sublingual film containing BXCL501 (Dexmedetomidine)

Agitation

Phase 1 · small_molecule · completed

1 trials project

Talabostat Mesylate

Cancer of Pancreas

Phase 1 · small_molecule · terminated

1 trials project

Dexmedetomidine

Schizophrenia Agitation

Approved · small_molecule · active

1 trials project

Sublingual film containing Igalmi

Bipolar Disorder

Approved · small_molecule · completed

1 trials

Patents (8)

patent

US 12364683

Non-sedating dexmedetomidine treatment regimens

Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12138247

Non-sedating dexmedetomidine treatment regimens

Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12109196

Non-sedating dexmedetomidine treatment regimens

Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12090140

Non-sedating dexmedetomidine treatment regimens

Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11998528

Non-sedating dexmedetomidine treatment regimens

Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11998529

Non-sedating dexmedetomidine treatment regimens

Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11931340

Use of sublingual dexmedetomidine for the treatment of agitation

Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11890272

Non-sedating dexmedetomidine treatment regimens

Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)